Jaguar Health, Inc. (JAGX)
NASDAQ: JAGX · Real-Time Price · USD
0.926
+0.053 (6.01%)
At close: Dec 20, 2024, 4:00 PM
0.951
+0.025 (2.76%)
After-hours: Dec 20, 2024, 7:04 PM EST
Jaguar Health Revenue
Jaguar Health had revenue of $3.11M in the quarter ending September 30, 2024, with 10.49% growth. This brings the company's revenue in the last twelve months to $10.48M, down -2.25% year-over-year. In the year 2023, Jaguar Health had annual revenue of $9.76M, down -18.36%.
Revenue (ttm)
$10.48M
Revenue Growth
-2.25%
P/S Ratio
0.41
Revenue / Employee
$213,878
Employees
49
Market Cap
10.92M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 9.76M | -2.20M | -18.36% |
Dec 31, 2022 | 11.96M | 7.62M | 175.80% |
Dec 31, 2021 | 4.34M | -5.05M | -53.81% |
Dec 31, 2020 | 9.39M | 3.61M | 62.51% |
Dec 31, 2019 | 5.78M | 1.36M | 30.77% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2007 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Evoke Pharma | 8.62M |
Ensysce Biosciences | 4.42M |
Immuron | 3.27M |
Apollomics | 2.10M |
BioRestorative Therapies | 377.00K |
Talphera | 281.00K |
JAGX News
- 2 days ago - Jaguar Health Announces Import of Coca Leaf From Peru by Joint Venture Magdalena Biosciences for Research in Treating Mental Health Indications - Accesswire
- 3 days ago - Phase 2 Study Initiated to Evaluate Jaguar Health's Crofelemer for Microvillus Inclusion Disease (MVID), an Ultrarare Congenital Diarrheal Disorder - Accesswire
- 4 days ago - FDA Approves Orphan-Drug Designation for Jaguar Health's Crofelemer for Treatment of Diarrhea in Cholera - Accesswire
- 8 days ago - Ladenburg Thalmann to Host Scientific Showcase December 18, 2024 About Rare Disease Clinical Development Efforts for Jaguar Health's Crofelemer - Accesswire
- 9 days ago - Significant Positive Results with Jaguar Health's Crofelemer for Cancer Therapy-Related Diarrhea (CTD) in Breast Cancer Patients Presented at San Antonio Breast Cancer Symposium (SABCS) - Accesswire
- 12 days ago - Poster Presentation Describing the Significant Results of Crofelemer for Cancer Therapy-Related Diarrhea (CTD) in Breast Cancer Patients to Take Place December 11, 2024 at San Antonio Breast Cancer Symposium (SABCS) - Accesswire
- 15 days ago - U.S. Investigator-Initiated Trial (IIT) to Evaluate Jaguar Health's Crofelemer for Short Bowel Syndrome with Intestinal Failure (SBS-IF) Begins - Accesswire
- 16 days ago - Article about Canalevia-CA1, Jaguar Health's Prescription Drug Conditionally Approved by the FDA for the Treatment of Chemotherapy-Induced Diarrhea in Dogs, Published in PetVet Magazine - Accesswire